In this section:

14 January 2019

New Psoriatic Arthritis Treatment Approved for Use in Scotland

The Scottish Medicines Consortium approves Xeljanz (tofacitinib) for the treatment of psoriatic arthritis.

The Scottish Medicines Consortium (SMC) has today published its acceptance of Xeljanz (tofacitinib) as a treatment for psoriatic arthritis in Scotland.

Xeljanz may be prescribed in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have not responded adequately to at least two conventional DMARDs - disease-modifying anti-rheumatic drugs (medicines that stop or slow disease progression), given either alone or in combination.

Xeljanz, which is taken by tablet, works differently to any of the other treatments that are currently available for psoriatic arthritis. It belongs to a class of medications known as JAK inhibitors and works by blocking the actions of a group of proteins called Janus Kinases (JAKs) which are involved in causing the inflammation in psoriatic arthritis. By blocking their actions, tofacitinib reduces the inflammation and other symptoms of psoriatic arthritis.

We will be publishing more information on Xeljanz for psoriatic arthritis soon. In the meantime, please get in touch with us if you have any questions.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF

Email: mail@psoriasis-association.org.uk

Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.